Background Acromegaly is a rare disease due to chronic growth hormone (GH) excess and the consequent increase in insulin-like growth factor-1 (IGF-1) levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. The association between hyperinsulinemia/impaired glucose tolerance and an increased risk of cancer has been clarified. Insulin has a mitogenic effect through its interaction with the IGF-1 receptor (IGF-1R) that also binds IGF-1. On the other hand, metformin, an anti-hyperglycemic drug that decreases serum levels of insulin and IGF-1, could have a protective role in the treatment of endocrine tumors. Methods A retrospective, observational, multicenter study in 197 acromegalic patients, receiving/not receiving metformin, was performed to assess whether the prevalence of neoplasms might be correlated with insulin resistance and could eventually be modified by metformin treatment. Results In general, the occurrence of secondary neoplasia among our patients was significantly (pV = 0.035) associated with a positive family history of malignancy and with disease duration; a trend towards significance was observed in patients aged > 50 years. Acromegalic subjects who had undergone surgery showed a lower probability of developing a malignant tumor, whereas a higher prevalence of malignancies was observed in obese patients. No significant statistical difference was found when comparing metformin-treated or -untreated subjects for the presence of a second tumor. More interestingly, a trend towards statistical significance (pV = 0.065) was demonstrated in the metformin-treated group for the onset of a benign neoplasm. Conclusion Metformin could act directly on tumor cell metabolism and may have an adjuvant role in benign lesion progression.

The prevalence of secondary neoplasms in acromegalic patients:possible preventive and/or protective role of metformin / Costa, Denise; Ceccato, Filippo; Lauretta, Rosa; Mercuri, Valeria; D'Amico, Tania; De Vito, Corrado; Scaroni, Carla; Appetecchia, Marialuisa; Gargiulo, Patrizia. - In: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1341-9625. - 26:6(2021), pp. 1015-1021. [10.1007/s10147-021-01895-y]

The prevalence of secondary neoplasms in acromegalic patients:possible preventive and/or protective role of metformin

Denise Costa
Primo
;
Valeria Mercuri;Tania D'Amico;Corrado De Vito;Patrizia Gargiulo
2021

Abstract

Background Acromegaly is a rare disease due to chronic growth hormone (GH) excess and the consequent increase in insulin-like growth factor-1 (IGF-1) levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose homeostasis. The association between hyperinsulinemia/impaired glucose tolerance and an increased risk of cancer has been clarified. Insulin has a mitogenic effect through its interaction with the IGF-1 receptor (IGF-1R) that also binds IGF-1. On the other hand, metformin, an anti-hyperglycemic drug that decreases serum levels of insulin and IGF-1, could have a protective role in the treatment of endocrine tumors. Methods A retrospective, observational, multicenter study in 197 acromegalic patients, receiving/not receiving metformin, was performed to assess whether the prevalence of neoplasms might be correlated with insulin resistance and could eventually be modified by metformin treatment. Results In general, the occurrence of secondary neoplasia among our patients was significantly (pV = 0.035) associated with a positive family history of malignancy and with disease duration; a trend towards significance was observed in patients aged > 50 years. Acromegalic subjects who had undergone surgery showed a lower probability of developing a malignant tumor, whereas a higher prevalence of malignancies was observed in obese patients. No significant statistical difference was found when comparing metformin-treated or -untreated subjects for the presence of a second tumor. More interestingly, a trend towards statistical significance (pV = 0.065) was demonstrated in the metformin-treated group for the onset of a benign neoplasm. Conclusion Metformin could act directly on tumor cell metabolism and may have an adjuvant role in benign lesion progression.
acromegaly; secondary tumor prevalence; metformin; benign neoplasm
01 Pubblicazione su rivista::01a Articolo in rivista
The prevalence of secondary neoplasms in acromegalic patients:possible preventive and/or protective role of metformin / Costa, Denise; Ceccato, Filippo; Lauretta, Rosa; Mercuri, Valeria; D'Amico, Tania; De Vito, Corrado; Scaroni, Carla; Appetecchia, Marialuisa; Gargiulo, Patrizia. - In: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. - ISSN 1341-9625. - 26:6(2021), pp. 1015-1021. [10.1007/s10147-021-01895-y]
File allegati a questo prodotto
File Dimensione Formato  
Costa_The-prevalence_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 463.14 kB
Formato Adobe PDF
463.14 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1517831
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact